Development of immuno-gene therapy strategy using co-stimulatorymolecule linking local treatment and systemic anti-tumor effect.
| Project/Area Number |
23791583
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
SAITO Ryuta 東北大学, 大学院・医学系研究科, 助教 (10400243)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2011: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | 中枢神経系薬剤送達 / 腫瘍ワクチン / 脳腫瘍 / 化学療法 / 免疫治療 / 共刺激因子 / 薬剤送達 / 局所治療 / OX40 |
|---|
| Research Abstract |
In this study, we confirmed that co-stimulatory molecule OX-40 plays pivotal role in inducing strong anti-tumor efficacy. Using OX-40 agonistic antibody, immunostimulatory effect was evaluated. Induction of anti-tumor effect was strongest when OX-40 signal was activated together with subcutaneous tumor vaccination. Thus, we tried to develop new immunotherapeutic strategy against glioblastoma. Activation of OX-40 signaling can be promising immunotherapy for glioblastoma.
|
Report
(3 results)
Research Products
(47 results)
